Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
Vericel Corporation (NASDAQ:VCEL) will report its third-quarter 2022 financial results on November 9, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) will report its third-quarter 2022 financial results on November 9, 2022. The company specializes in advanced therapies for sports medicine and severe burn care, marketing two prominent cell therapy products: MACI and Epicel. A conference call will be held at 8:30 a.m. ET to discuss the results and key business highlights. Interested parties can join via a live webcast on the company's Investor Relations website. Presentation slides will also be available during the call.
Positive
- Scheduled earnings call on November 9, 2022, which may provide insights into financial performance.
Negative
- None.
Details
News Market Reaction – VCEL
The recorded move for VCEL in the trading session of this news was +4.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and certain business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.
To participate by telephone, please register here to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until November 9, 2023.
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
Media Contact:
Julie Downs
media@vcel.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.